Furthermore, these studies revealed that SGLT-2 inhibitors could attenuate the accumulation of amyloid-beta (Aβ) plaques, a hallmark of Alzheimer’s disease [51]. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.